ラジオ波焼灼装置市場：製品タイプ別、用途別、地域別、2026～2032年

ラジオ波焼灼装置の市場評価、2026～2032年

ラジオ波焼灼技術の進歩が市場の成長を後押ししています。これらの技術革新により、治療の精度、有効性、安全性が向上し、より信頼性が高く、利用しやすいものとなっています。したがって、ラジオ波焼灼技術の進歩は、2024年に47億4,000万米ドルを超える市場規模の成長を急増させ、2032年には100億8,000万米ドルの評価額に達します。

外来手術への嗜好が高まっているのは、その利便性、費用対効果、入院期間の短縮が背景にあります。ラジオ波焼灼装置は低侵襲であり、最小限の回復時間で済む手技を提供することでこの動向に合致し、患者とヘルスケア提供者の双方にとって魅力的な選択肢となっています。したがって、外来患者による処置の人気の高まりにより、市場は2026～2032年にかけてCAGR 10.90％で成長します。

ラジオ波焼灼装置市場の定義/概要

ラジオ波焼灼（RFA）装置は、高周波電流を利用して制御された熱を発生させ、これを特定の組織や神経に適用して凝固や破壊を誘導する特殊な医療機器です。この低侵襲処置は、インターベンショナルラジオロジー、疼痛管理、腫瘍学、心臓学、皮膚科学など、さまざまな医療分野で広く用いられています。RFAは、周囲の組織を損傷することなく、患部を正確に狙い撃ちする能力が特に評価されており、いくつかの疾患に対して安全で効果的な治療選択肢となっています。

RFAは、腰痛や関節痛などの慢性疼痛の治療や、特定の種類のがん、不整脈、静脈瘤、良性・悪性腫瘍などの疼痛管理によく用いられています。疼痛管理では、RFAは神経信号を遮断することで長期にわたる緩和をもたらし、腫瘍学や心臓学では腫瘍や異常な心臓組織の切除に用いられます。

RFA装置の現在進行中の技術的進歩は、その設計を改善し、エネルギー供給システムを強化し、手技効率を高めることを目的としています。これらの技術革新により、治療精度が向上し、回復時間が短縮され、RFAで治療できる病態の範囲が広がっています。調査はまた、新たな病態を対象とし、治療プロトコルを改良するためにRFAを応用拡大することにも重点を置いており、RFAを現代の医療介入における重要なツールとして位置づけています。

高齢者人口と慢性疾患負担の増加は、どのようにラジオ波焼灼装置市場の成長を急増させるのか？

世界の高齢化人口の増加と慢性疾患の増加が、ラジオ波焼灼装置市場の成長を後押ししています。WHOによると、60歳以上の世界人口は2050年までに21億人に達します。CDCは、高齢者の85％が少なくとも1つの慢性疾患を抱えており、2022年時点で60％が2つ以上の慢性疾患を抱えていると報告しています。高齢者人口の増加により、RFA治療に対するメディケア支出は2020～2022年の間に32%増加しました。

米国国立がん研究所は、2021年に新たに190万人のがん患者が発生し、肝臓がん患者は毎年2.5％増加すると報告しています。GLOBOCAN 2022によると、早期肝がん治療の約25%でRFAが使用されています。小型肝細胞がん症例におけるRFAの臨床的成功率は97％と報告されています。米国心臓協会は、2022年の心臓アブレーション治療件数は45万件以上で、2020年から15％増加したと報告しています。メディケアのデータでは、2020～2023年の間に心臓RFA治療に対する償還請求が28％増加しました。

FDAは2021～2023年の間に8つの新しいRFA機器を承認しました。インターベンショナルラジオロジー学会は、2022年に新しいRFAシステムにより手技時間が40％短縮したと報告しました。2020～2023年にかけて、先進的RFAシステムの病院での採用が35％増加しました。American Journal of Managed Care誌は、2022年に従来の手術と比較してRFAの費用が45％低いと報告しました。Healthcare Cost and Utilization Project（HCUP）2023によると、平均在院日数は5.2日（手術）から1.3日（RFA）に短縮しました。保険請求データでは、RFAによる治療総費用は従来の手術に比べ30％低くなりました。

限られた熟練医療従事者がラジオ波焼灼装置市場の成長をどのように阻害しているか？

米国麻酔科学会は、2022年には訓練されたRFA専門医が22％不足すると報告しています。米国医科大学協会（Association of American Medical Colleges）によると、2023年時点で高度なRFA技術の訓練を受けているインターベンショナルラジオロジストは35%に過ぎません。RFA手技のトレーニング費用は2020～2022年にかけて45％増加し、小規模医療施設での導入が制限されています（Society of Interventional Radiology）。RFA機器の平均コストは、2023年時点で85,000ドルから175,000ドルです。CMSのデータによれば、メディケアの償還は手技費用総額の60～70％しかカバーされていません。

病院によるRFA機器への投資は、予算の制約により2022年には18％減少しました。

FDAは、2020～2022年にかけてRFA手技に関連する有害事象報告が15％増加したと報告しました。臨床研究では、心臓RFA手技の合併症率は4.7％でした（米国心臓協会、2023年）。複合腫瘍アブレーション症例では8.3％の技術的失敗率が報告されています（Journal of Interventional Radiology、2022年）。新しいRFA機器のFDA承認期間は、2022年には平均18ヵ月であったのに対し、他の医療機器では12ヵ月でした。規制遵守コストは2020～2023年の間に28％増加しました（医療機器製造業者協会）。

目次

第1章 イントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 市場概要

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 ラジオ波焼灼装置市場：製品タイプ別

• 概要
• 再利用可能
• 使い捨て
• 資本設備

第6章 ラジオ波焼灼装置市場：用途別

• 概要
• 心臓病学および心リズム管理
• 婦人科
• 疼痛管理
• 外科腫瘍学
• 腫瘍学

第7章 ラジオ波焼灼装置市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 競合情勢

• 概要
• 各社の市場ランキング
• 主な発展戦略

第9章 企業プロファイル

• Hologic, Inc.
• Medtronic
• AngioDynamics, Inc.
• Boston Scientific Corporation
• St. Jude Medical, Inc.
• Halyard Health, Inc.
• Stryker, C. R. Bard, Inc.
• AtriCure, Inc.
• Johnson & Johnson
• BIOTRONIK Schweiz AG

第10章 主な発展

• 製品上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第11章 付録

• 関連調査

Radiofrequency Ablation Devices Market Valuation - 2026-2032

Advancements in radiofrequency ablation technology are fueling market growth. These innovations have enhanced the precision, efficacy, and safety of treatments, making them more reliable and accessible. Thus, advancements in radiofrequency ablation technology surge the growth of market size surpassing USD 4.74 Billion in 2024 to reach a valuation of USD 10.08 Billion by 2032.

The growing preference for outpatient procedures is driven by their convenience, cost-effectiveness, and shorter hospital stays. Radiofrequency ablation devices, being minimally invasive, align with this trend by offering procedures that require minimal recovery time, making them an attractive option for both patients and healthcare providers. Thus, the increasing popularity of outpatient procedures enables the market to grow at a CAGR of 10.90% from 2026 to 2032.

Radiofrequency Ablation Devices Market: Definition/ Overview

Radiofrequency ablation (RFA) devices are specialized medical instruments that utilize high-frequency electrical currents to generate controlled heat, which is applied to specific tissues or nerves to induce coagulation or destruction. This minimally invasive procedure is widely used across various medical disciplines, including interventional radiology, pain management, oncology, cardiology, and dermatology. RFA is particularly valued for its ability to precisely target affected areas without damaging surrounding tissues, making it a safe and effective treatment option for several conditions.

Common applications of RFA include the treatment of chronic pain conditions, such as back pain and joint pain, as well as the management of specific types of cancer, cardiac arrhythmias, varicose veins, and both benign and malignant tumors. In pain management, RFA offers long-lasting relief by disrupting nerve signals, while in oncology and cardiology, it is used to ablate tumors or aberrant heart tissue.

Ongoing technological advancements in RFA devices aim to improve their design, enhance energy delivery systems, and increase procedural efficiency. These innovations are enhancing treatment precision, reducing recovery times, and expanding the range of conditions that can be treated with RFA. Research is also focused on broadening the applications of RFA to target new medical conditions and refine treatment protocols, positioning RFA as a crucial tool in modern medical interventions.

How does the Growing Geriatric Population & Chronic Disease Burden Surge the Growth of the Radiofrequency Ablation Devices Market?

An increasing aging population and rising chronic disorders globally propel the growth of the radiofrequency ablation devices market. According to the WHO, the global population aged 60+ will reach 2.1 billion by 2050 The CDC reported that 85% of older adults have at least one chronic condition, with 60% having two or more as of 2022. Medicare spending on RF ablation procedures increased by 32% between 2020-2022 due to rising elderly population demands

The National Cancer Institute reported 1.9 million new cancer cases in 2021, with liver cancer cases increasing by 2.5% annually. According to GLOBOCAN 2022, RF ablation was used in approximately 25% of early-stage liver cancer treatments. Clinical success rates of 97% were reported for RF ablation in small hepatocellular carcinoma cases. The American Heart Association reported 450,000+ cardiac ablation procedures in 2022, a 15% increase from 2020. Medicare data showed a 28% increase in reimbursement claims for cardiac RF ablation procedures between 2020-2023

FDA approved 8 new RF ablation devices between 2021-2023. The Society of Interventional Radiology reported a 40% reduction in procedure time with newer RF ablation systems in 2022. Hospital adoption of advanced RF ablation systems increased by 35% from 2020 to 2023. The American Journal of Managed Care reported 45% lower costs for RF ablation compared to traditional surgery in 2022. Average hospital stay reduced from 5.2 days (surgery) to 1.3 days (RF ablation) according to the Healthcare Cost and Utilization Project (HCUP) 2023. Insurance claims data showed 30% lower total treatment costs with RF ablation versus conventional surgery.

How do Limited Skilled Healthcare Professionals Impede the Growth of the Radiofrequency Ablation Devices Market?

The American Society of Anesthesiologists reported a 22% shortage of trained RF ablation specialists in 2022. According to the Association of American Medical Colleges, only 35% of interventional radiologists are trained in advanced RF ablation techniques as of 2023. Training costs for RF ablation procedures increased by 45% from 2020 to 2022, limiting adoption in smaller healthcare facilities (Society of Interventional Radiology). The average cost of RF ablation equipment ranges from $85,000 to $175,000 as of 2023. Medicare reimbursement covers only 60-70% of the total procedure cost, according to CMS data 2022

Hospital investment in RF ablation equipment decreased by 18% in 2022 due to budget constraints.

The FDA reported a 15% increase in adverse event reports related to RF ablation procedures from 2020 to 2022. Clinical studies showed complication rates of 4.7% for cardiac RF ablation procedures (American Heart Association, 2023). Technical failure rates of 8.3% were reported in complex tumor ablation cases (Journal of Interventional Radiology, 2022). FDA approval time for new RF ablation devices averaged 18 months in 2022, compared to 12 months for another medical devices. Regulatory compliance costs increased by 28% between 2020-2023 (Medical Device Manufacturers Association).

Category-Wise Acumens

How the Advanced Technology in Disposable RFA Devices Surge the Growth of Disposable Equipment Segment?

The disposable equipment segment dominates the radiofrequency ablation (RFA) devices market, driven by the efficiency and safety of medical procedures. The advanced technology integrated into disposable RFA devices enables the creation of large areas of coagulative necrosis in a controlled and precise manner. These devices are relatively low in toxicity, reducing the likelihood of adverse side effects and minimizing the risk of complications, which further fuels their adoption across various medical specialties.

Disposable RFA devices have a reduced risk of cross-contamination. By using fresh, sterile equipment for each patient, the likelihood of infection or contamination is significantly lowered, enhancing patient safety and boosting confidence in treatment outcomes. Additionally, continuous technological advancements, such as improved electrode designs and the use of advanced materials, are further propelling the growth of this segment, as they enhance the precision, effectiveness, and ease of use of disposable RFA devices.

How does the Increasing Adoption of Effective Treatment for Cancerous Cells Accelerate the Growth of the Oncology Segment?

The oncology segment stands out as dominant in the radiofrequency ablation devices market, driven by its growing adoption as an effective treatment for cancerous cells, particularly in high-risk patients with unresectable or refractory tumors. RFA is increasingly used in surgical oncology to treat various types of cancer, offering a minimally invasive alternative to conventional surgery. Its ability to precisely target cancerous tissues while minimizing damage to surrounding healthy cells has made it a preferred option for addressing both primary and metastatic tumors. This is especially beneficial for patients with multiple tumors or those who cannot undergo open surgery, significantly improving their survival outcomes and overall quality of life.

The rising global prevalence of cancer is a major factor fueling the growth of this segment. As cancer cases increase, so does the demand for advanced, less invasive treatment options like RFA. The technology's ability to reduce potential side effects, shorten recovery times, and deliver precise results has made it a valuable tool in oncology. Moreover, continuous advancements in RFA technology, such as enhanced imaging guidance and the development of multi-electrode systems, have further boosted its efficacy in treating tumors.

Country/Region-wise Acumens

How does the Advanced Healthcare Infrastructure & High Healthcare Spending Accelerate the Growth of the Radiofrequency Ablation Devices Market in North America?

North America substantially dominates the radiofrequency ablation devices market driven by the advanced healthcare infrastructure and high healthcare investment. U.S. healthcare spending reached USD 4.3 Trillion in 2022, with 12% allocated to medical devices and technologies. The number of ambulatory surgery centers performing RF ablation in North America increased by 32% from 2020 to 2023. Canada's healthcare spending on minimally invasive procedures grew by 25% between 2020-2022, with RF ablation accounting for 18% of this growth.

The American Cancer Society reported 1.9 million new cancer cases in 2022, with liver cancer cases increasing 2.8% annually. According to the CDC, cardiovascular diseases affected 48% of adults over 20 in 2022, with 850,000+ requiring interventional procedures. The Heart Rhythm Society documented that atrial fibrillation affects 5.5 million Americans, with RF ablation procedures increasing by 38% from 2020 to 2023

Medicare expanded RF ablation procedure coverage by 35% between 2020-2023, covering 85% of total procedure costs. Private insurance claims for RF ablation procedures increased by 42% from 2020 to 2022. The average reimbursement rate for RF ablation procedures in the U.S. increased from $5,200 in 2020 to $6,800 in 2023.

How does the Rapidly Growing Geriatric Population & Disease Burden Escalate the Growth of the Radiofrequency Ablation Devices Market in the Asia Pacific?

Asia Pacific is anticipated to witness the fastest growth in the radiofrequency ablation devices market during the forecast period owing to the rising aging population and increasing diseases. According to WHO Western Pacific Region, the 65+ population in Asia Pacific reached 300 million in 2022, with an annual growth rate of 3.5%. China reported a 45% increase in liver cancer cases from 2020-2022, with RF ablation being used in 30% of early-stage treatments. Japan's Ministry of Health reported that 42% of its population will be over 60 by 2023, leading to a 28% increase in RF ablation procedures since 2020.

India's healthcare budget increased by 37% in 2022, with 15% allocated to advanced medical technologies including RF ablation (Indian Ministry of Health). South Korea's government provided USD 2.8 Billion in healthcare technology subsidies from 2020-2023, boosting RF ablation device adoption by 42%. Japan's Ministry of Health approved 28% more reimbursement for RF ablation procedures in 2022 compared to 2020, increasing accessibility.

Competitive Landscape

The Radiofrequency Ablation Devices Market is a dynamic and competitive landscape, driven by the increasing adoption of minimally invasive procedures. Key players in this market are continuously innovating to develop advanced RFA systems and accessories.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the radiofrequency ablation devices market include:

• Hologic, Inc.
• Medtronic
• AngioDynamics, Inc.
• Boston Scientific Corporation
• Jude Medical, Inc.
• Halyard Health, Inc.
• Stryker, C. R. Bard, Inc.
• AtriCure, Inc.
• Johnson & Johnson
• BIOTRONIK Schweiz AG

Latest Developments:

• In April 2022, AtriCure announced the EnCompass Clamp, a component of its Isolator Synergy ablation system, which provides parallel closure, uniform pressure, and tailored power via synergy radiofrequency, hence improving the efficiency of cardiac tissue ablation during cardiac surgery.
• In April 2022, Royal Philips announced the launch of the KODEX-EPD system, which improves imaging and mapping capabilities for RF ablation and includes the Tissue Engagement Viewer as well as support for the Medtronic DiamondTemp system.

Radiofrequency Ablation Devices Market, By Category

• Product Type:
• Disposable Equipment
• Capital Equipment
• Reusable Equipment
• Application:
• Oncology
• Cardiology and Cardiac Rhythm
• Management
• Gynecology
• Pain Management
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL RADIOFREQUENCY ABLATION DEVICES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL RADIOFREQUENCY ABLATION DEVICES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL RADIOFREQUENCY ABLATION DEVICES MARKET, BY PRODUCT TYPE

• 5.1 Overview
• 5.2 Reusable Equipment
• 5.3 Disposable Equipment
• 5.4 Capital Equipment

6 GLOBAL RADIOFREQUENCY ABLATION DEVICES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Cardiology & Cardiac Rhythm Management
• 6.3 Gynecology
• 6.4 Pain Management
• 6.5 Surgical Oncology
• 6.6 Oncology

7 GLOBAL RADIOFREQUENCY ABLATION DEVICES MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL RADIOFREQUENCY ABLATION DEVICES MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Hologic, Inc.
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Medtronic
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 AngioDynamics, Inc.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Boston Scientific Corporation
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 St. Jude Medical, Inc.
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Halyard Health, Inc.
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Stryker, C. R. Bard, Inc.
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 AtriCure, Inc.
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Johnson & Johnson
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 BIOTRONIK Schweiz AG
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research